A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Vamorolone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors ReveraGen BioPharma
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2018.
- 26 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Apr 2018.